Company Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.
Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jul 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Dr. James R. Porter Ph.D. |
Contact Details
Address: One Broadway Cambridge, Massachusetts United States | |
| Website | https://www.nuvalent.com |
Stock Details
| Ticker Symbol | NUVL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001861560 |
| CUSIP Number | 670703107 |
| ISIN Number | US6707031075 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James R. Porter Ph.D. | Chief Executive Officer, President & Director |
| Alexandra Balcom CPA, M.B.A. | Chief Financial Officer & Treasurer |
| Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Secretary |
| Darlene Noci | Chief Development Officer |
| Dr. Benjamin Lane Ph.D. | Senior Vice President of Technical Operations |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer |
| Henry Pelish Ph.D. | Chief Scientific Officer |
| John Soglia Ph.D. | Senior Vice President of Translational Development |
| Matthew Metivier | Senior Vice President of Human Resources |
| Prof. Matthew D. Shair Ph.D. | Founder, Head of Scientific Advisory Board & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 3 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 03, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 19, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |